Clay Thorp

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Durham, NC
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Mark Ballantyne, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Clay Thorp

Form 4 holding Director

Vigil Neuroscience, Inc.

Security class
Common Stock
Shares / value
1,556,030
Estimated value
$5,835,113
Report date
17 May 2022
Price
$3.75
Ownership
By Hatteras Venture Partners VI, L.P.
Form 4 holding Director

Vigil Neuroscience, Inc.

Security class
Common Stock
Shares / value
3,000
Estimated value
$11,250
Report date
16 May 2022
Price
$3.75
Ownership
Direct
Form 4 holding Director

Clearside Biomedical, Inc.

Security class
Stock Option (right to buy)
Shares / value
45,000
Estimated value
Report date
20 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

PhaseBio Pharmaceuticals Inc

Security class
Restricted Stock Units
Shares / value
0
Estimated value
Report date
19 May 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Clay Thorp

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .